On January 13, 2020 Human Longevity, Inc., an innovator in providing data-driven health intelligence and precision health to physicians and patients reported that the Oncology Division was sold to NeoGenomics (NASDAQ NEO) for $37 Million (Press release, Human Longevity, JAN 13, 2020, View Source [SID1234553107]). The financing, a cash transaction, closed on Friday, January 10, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

David Karow, MD, PhD, President and Chief Innovation Officer of Human Longevity, Inc., said, "The sale of this division allows us to focus entirely on longevity and extending the healthy, high-performance human lifespan. Additionally, it will provide the firm with additional working capital, along with the recent Series A2 round of financing, to grow domestically and internationally."